116 related articles for article (PubMed ID: 12894573)
1. CaSm antisense gene therapy: a novel approach for the treatment of pancreatic cancer.
Kelley JR; Fraser MM; Hubbard JM; Watson DK; Cole DJ
Anticancer Res; 2003; 23(3A):2007-13. PubMed ID: 12894573
[TBL] [Abstract][Full Text] [Related]
2. The cancer-associated Sm-like oncogene: a novel target for the gene therapy of pancreatic cancer.
Kelley JR; Brown JM; Frasier MM; Baron PL; Schweinfest CW; Vournakis JN; Watson DK; Cole DJ
Surgery; 2000 Aug; 128(2):353-60. PubMed ID: 10923016
[TBL] [Abstract][Full Text] [Related]
3. Bystander effect contributes to the antitumor efficacy of CaSm antisense gene therapy in a preclinical model of advanced pancreatic cancer.
Yan Y; Rubinchik S; Wood AL; Gillanders WE; Dong JY; Watson DK; Cole DJ
Mol Ther; 2006 Feb; 13(2):357-65. PubMed ID: 16226492
[TBL] [Abstract][Full Text] [Related]
4. CaSm-mediated cellular transformation is associated with altered gene expression and messenger RNA stability.
Fraser MM; Watson PM; Fraig MM; Kelley JR; Nelson PS; Boylan AM; Cole DJ; Watson DK
Cancer Res; 2005 Jul; 65(14):6228-36. PubMed ID: 16024624
[TBL] [Abstract][Full Text] [Related]
5. Establishing a murine pancreatic cancer CaSm model: up-regulation of CaSm is required for the transformed phenotype of murine pancreatic adenocarcinoma.
Yan Y; Rubinchik S; Watson PM; Kelley JR; Fraser MM; Wood AL; Dong JY; Gillanders WE; Boylan AM; Watson DK; Cole DJ
Mol Ther; 2005 Mar; 11(3):363-72. PubMed ID: 15727932
[TBL] [Abstract][Full Text] [Related]
6. CaSm/gemcitabine chemo-gene therapy leads to prolonged survival in a murine model of pancreatic cancer.
Kelley JR; Fraser MM; Schweinfest CW; Vournakis JN; Watson DK; Cole DJ
Surgery; 2001 Aug; 130(2):280-8. PubMed ID: 11490361
[TBL] [Abstract][Full Text] [Related]
7. Interferon-alpha and antisense K-ras RNA combination gene therapy against pancreatic cancer.
Hatanaka K; Suzuki K; Miura Y; Yoshida K; Ohnami S; Kitade Y; Yoshida T; Aoki K
J Gene Med; 2004 Oct; 6(10):1139-48. PubMed ID: 15452878
[TBL] [Abstract][Full Text] [Related]
8. CaSm: an Sm-like protein that contributes to the transformed state in cancer cells.
Schweinfest CW; Graber MW; Chapman JM; Papas TS; Baron PL; Watson DK
Cancer Res; 1997 Jul; 57(14):2961-5. PubMed ID: 9230209
[TBL] [Abstract][Full Text] [Related]
9. Intraperitoneal injection of adenovirus expressing antisense K-ras RNA suppresses peritoneal dissemination of hamster syngeneic pancreatic cancer without systemic toxicity.
Miura Y; Ohnami S; Yoshida K; Ohashi M; Nakano M; Ohnami S; Fukuhara M; Yanagi K; Matsushita A; Uchida E; Asaka M; Yoshida T; Aoki K
Cancer Lett; 2005 Jan; 218(1):53-62. PubMed ID: 15639340
[TBL] [Abstract][Full Text] [Related]
10. Pigment epithelium-derived factor gene therapy inhibits human pancreatic cancer in mice.
Hase R; Miyamoto M; Uehara H; Kadoya M; Ebihara Y; Murakami Y; Takahashi R; Mega S; Li L; Shichinohe T; Kawarada Y; Kondo S
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8737-44. PubMed ID: 16361561
[TBL] [Abstract][Full Text] [Related]
11. Adenoviral expression of XIAP antisense RNA induces apoptosis in glioma cells and suppresses the growth of xenografts in nude mice.
Naumann U; Bähr O; Wolburg H; Altenberend S; Wick W; Liston P; Ashkenazi A; Weller M
Gene Ther; 2007 Jan; 14(2):147-61. PubMed ID: 16957768
[TBL] [Abstract][Full Text] [Related]
12. Molecular target-based therapy of pancreatic cancer.
Lebedeva IV; Sarkar D; Su ZZ; Gopalkrishnan RV; Athar M; Randolph A; Valerie K; Dent P; Fisher PB
Cancer Res; 2006 Feb; 66(4):2403-13. PubMed ID: 16489047
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA.
Zhang YA; Nemunaitis J; Samuel SK; Chen P; Shen Y; Tong AW
Cancer Res; 2006 Oct; 66(19):9736-43. PubMed ID: 17018633
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional silencing of ETS-1 efficiently suppresses angiogenesis of pancreatic cancer.
Lefter LP; Dima S; Sunamura M; Furukawa T; Sato Y; Abe M; Chivu M; Popescu I; Horii A
Cancer Gene Ther; 2009 Feb; 16(2):137-48. PubMed ID: 18772901
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications.
Talar-Wojnarowska R; Malecka-Panas E
Med Sci Monit; 2006 Sep; 12(9):RA186-93. PubMed ID: 16940943
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy developments for pancreatic cancer.
Bhattacharyya M; Lemoine NR
Best Pract Res Clin Gastroenterol; 2006 Apr; 20(2):285-98. PubMed ID: 16549328
[TBL] [Abstract][Full Text] [Related]
17. Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter.
Jacob D; Davis J; Zhu H; Zhang L; Teraishi F; Wu S; Marini FC; Fang B
Clin Cancer Res; 2004 May; 10(10):3535-41. PubMed ID: 15161713
[TBL] [Abstract][Full Text] [Related]
18. Adenoviral gene therapy for pancreatic cancer: where do we stand?
Kuhlmann KF; Gouma DJ; Wesseling JG
Dig Surg; 2008; 25(4):278-92. PubMed ID: 18635930
[TBL] [Abstract][Full Text] [Related]
19. Cloning and analysis of human UroplakinII promoter and its application for gene therapy in bladder cancer.
Zhu HJ; Zhang ZQ; Zeng XF; Wei SS; Zhang ZW; Guo YL
Cancer Gene Ther; 2004 Apr; 11(4):263-72. PubMed ID: 14963492
[TBL] [Abstract][Full Text] [Related]
20. Fiber-chimeric adenoviruses expressing fibers from serotype 16 and 50 improve gene transfer to human pancreatic adenocarcinoma.
Kuhlmann KF; van Geer MA; Bakker CT; Dekker JE; Havenga MJ; Elferink RP; Gouma DJ; Bosma PJ; Wesseling JG
Cancer Gene Ther; 2009 Jul; 16(7):585-97. PubMed ID: 19180144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
